Dr. Homaira Akbari
Dr. Homaira Akbari's purchase track record
Dr. Homaira Akbari has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/15/2022 | LSTR | $77K | -5.3% | -4.9% | -7.7% |
| 2/24/2022 | LSTR | $303K | +0.2% | +0.6% | -2.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Jim Cramer Gives BW a Chance With One Condition. Jim Cramer mentioned Babcock & Wilcox Enterprises Inc. (BW) as a stock that could be worth watching, but only if a specific condition is met. The analyst highlighted that BW is currently trading near the lower end of its 52‑week range and its RSI is below 30, suggesting it may be oversold. The comment comes as the company faces a challenging bond market environment, which could impact its financing costs.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Landstar System Analyst Targets Adjusted Amid Supply Chain Focus. Several analysts have revised their price targets for Landstar System, with Truist and JP Morgan cutting their expectations to $175 and $181 respectively, while Wells Fargo keeps an overweight rating at $225. The adjustments come as the company remains a focus for investors watching supply‑chain pressures in the trucking sector. Landstar’s stock is near its 200‑day moving‑average support level of $178.14, adding context to the recent target revisions.
Transaction History
| QMLS | ▲ Buy | Grant | 8,681 | $0 | 10/1/2026 | View on chart |
| QMLS | ▲ Buy | Grant | 9,583 | $0 | 9/1/2026 | View on chart |
| QMLS | ▲ Buy | Grant | 6,038 | $0 | 9/1/2026 | View on chart |
| BW | ▲ Buy | Option Exercise | 3,021 | $64K | 5/15/2026 | View on chart |
| LSTR | ▲ Buy | Grant | 825 | $0 | 5/6/2026 | View on chart |
| LSTR | ▲ Buy | Grant | 1,043 | $0 | 5/19/2025 | View on chart |
| LSTR | ▲ Buy | Grant | 830 | $0 | 5/8/2024 | View on chart |
| LSTR | ▲ Buy | Grant | 851 | $0 | 5/11/2023 | View on chart |
| LSTR | ▲ Buy | Grant | 969 | $0 | 5/12/2022 | View on chart |
| LSTR | ▲ Buy | Open Market | 500 | $77K | 3/15/2022 | View on chart |
| LSTR | ▲ Buy | Open Market | 2,000 | $303K | 2/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
QumulusAI mentioned in AI pricing and IT stock roundups
QumulusAI was included in a Benzinga list of information technology stocks moving during Wednesday's intraday session. Separately, a Futurum Research report highlighted how agentic AI could significantly increase token usage, potentially shifting the industry away from per-token pricing models. These mentions place the company within broader discussions on AI infrastructure and market activity.
QumulusAI mentioned in AI pricing and IT stock roundups. QumulusAI was included in a Benzinga list of information technology stocks moving during Wednesday's intraday session. Separately, a Futurum Research report highlighted how agentic AI could significantly increase token usage, potentially shifting the industry away from per-token pricing models. These mentions place the company within broader discussions on AI infrastructure and market activity.